24/7 Market News Snapshot 13 March, 2025 – COSCIENS Biopharma Inc. Common Stock (NASDAQ:CSCI)

March 13, 2025

DENVER, Colo., 13 March, 2025 (247marketnews.com) – (NASDAQ:CSCI) are discussed in this article.
COSCIENS Biopharma Inc. (CSCI), a life sciences innovator focused on developing a diversified range of cosmeceutical, nutraceutical, and pharmaceutical products, commenced trading today at $2.22, showcasing a significant increase to $3.018, marking a surge of 12.19%. The previous day’s close at $2.690 illustrates heightened investor interest, reflected in the current trading volume of 670,020 shares. This bullish momentum suggests robust buying pressure, likely fueled by favorable market sentiment and recent company developments, including the initiation of their Phase 2a clinical efficacy study for the novel compound Avenanthramides.

The AvenActive study, part of COSCIENS’ efforts to explore avenanthramides for managing inflammation-related conditions, is a key milestone for the company. Following promising results from Phase 1, which demonstrated a notable safety profile with no significant adverse clinical events among the 72 participants, the company has received the endorsement from the Data Safety and Monitoring Board to progress further.

The Phase 2a study is set to begin patient treatment on March 14, 2025, enrolling 20 participants with mild to moderate inflammation. This stage aims to evaluate the efficacy of two specific dosing regimens—480 mg and 960 mg per day—building on earlier findings regarding the compound’s bioactivities.

Dr. Jean-Claude Tardif, the principal investigator, expressed confidence in the study’s potential, stating that the results from Phase 1 establish a solid basis for evaluating the beneficial effects of avenanthramides in inflamed subjects. COSCIENS’ President and CEO, Gilles Gagnon, underscored the importance of this advancement, noting their focus on potential out-licensing and partnerships designed to elevate the company’s position in the realm of natural health and wellness solutions. Through these developments, COSCIENS Biopharma is poised to significantly impact patient care in inflammation management.

Related news for (CSCI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.